Biogen, Eisai BACE drug cuts amyloid beta in the brain, but there’s no hard data to show it does anything important for cognition
Just after Merck $MRK research raised serious doubts about the BACE approach to tackling Alzheimer’s disease, researchers for Biogen $BIIB and Eisai are fighting against the tide this week. And they have a long way to go before they start persuading they may have something of value for patients.
The team focused on the oral BACE drug elenbecestat says the drug is doing what it’s intended to do, cutting down on the amount of amyloid beta in the brains of patients with a mild form of the disease and producing a numerical decline in the rate at which patients’ cognition spirals downward.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.